Dr. Tolin said the summary provided was simply to guide the 
discussion and possibly be used by IBCs and investigators as they 
go through the proposed changes. She said it allows cross- 
reference on specific paragraph numbers and sections. She said 
it was not intended to be included in the NIH Guidelines but to 
be used in aiding the discussion of the proposal and as an 
appropriate review of containment. 
Dr. Korwek said he did not have much to add to what had already 
been said. However, he had found some inconsistencies as well 
and felt there was some language that needed to be clarified. He 
said he felt Dr. Tolin' s summary was tremendously helpful. He 
wished it could be included in the NIH Guidelines, because he 
thought it had aided him greatly in his understanding of the 
proposed amendments. 
Dr. Epstein asked for clarification on the issue of the 
two-thirds of a viral genome and asked how the original language 
had been derived. Further, he wanted to know if it indeed would 
exempt experiments in Class II. A. which heretofore had not been 
exempted under the NIH Guidelines as currently constructed. 
Dr. Hughes replied to this question by stating that there was an 
error in the document. The intent had been to classify all 
injection transgenics as exempt because everyone on the working 
group felt that if an investigator went to the trouble of making 
rather expensive large transgenic animals, he would not let them 
loose in the environment. The logic was that a viral segment 
that was non-mobilizable was really no different than other DNA 
and should, therefore, fall into the same classification. He 
said what was left in the document was remnants of a discussion 
of whether or not these types of experiments should be exempt or 
done at the BL1-N level. He said he personally believed they 
should be exempt, but he did not want to imply that this was the 
consensus of the working group. 
Dr. McGarrity said he had no problem in seeing them done at the 
BL1 level. The intent was that IBCs would be looking at these 
experiments . 
Dr. Gottesman suggested that if they were to all be at the BL1 
level, then the sentence in paragraph 37 could be deleted. 
However, Dr. Hughes said it may have been placed in the proposal 
to allow for experiments that will take place at BL1-N and would 
require notification to IBCs but no review. Dr. Gottesman said 
her interpretation was that the Section III-B portion of the NIH 
Guidelines would remain in place, and experiments under Section 
III-B still require IBC review. None of the animal experiments 
have yet fallen into Section III-C which would allow for prior 
notification with no review required by IBCs. She said she would 
be concerned about placing these experiments in Section III-C, 
because it involves a judgment about whether the virus is going 
Recombinant DNA Research, Volume 13 
[61] 
